BioVersys and Partners’ Phase 2a TB Trial Results Published in New England Journal of Medicine

19 February 2026

BioVersys press release

— Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment of patients with TB.
— The results, published in the prestigious New England Journal of Medicine, underscore the significant potential of AlpE to shape the future of TB treatment.

Alpibectir is a small molecule acting through a novel mode of action, and represents a totally new concept of overcoming resistance by potentiating the activity of an existing antibiotic, ethionamide (Eto).

The Phase 2a bEto-TB clinical trial was conducted in South Africa through a consortium of three partners, TASK, GSK and BioVersys, and was completed in April 2024. AlpE delivered a promising clinical proof of concept in a 7-day early bactericidal activity study, conducted in patients with pulmonary TB. AlpE seeks to offer a replacement for isoniazid in the current first-line regimen or to be added as a novel bactericidal drug to future regimens including those of TB meningitis.

Read the full press release here.

Source: BioVersys